NV-ENCONNEX
21.11.2019 17:02:07 CET | Business Wire | Press release
Enconnex announced today that it has acquired assets of Active Energy Solutions (AES), a division of Methode Electronics, Inc., solidifying the long-term relationship between the two firms. Under an exclusive distribution agreement with AES, Enconnex has been offering the AC6000 uninterruptible power supply (UPS) to its customers. Enconnex has established a new manufacturing facility in its Reno, Nev., headquarters and incorporated the product into its integrated data center solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005220/en/
“This acquisition is the logical extension of our strategic partnership with AES,” said Thane Moore, Director of Product Line Management, Enconnex. “The AC6000 is a robust yet eco-friendly UPS that offers the advanced features needed to support today’s IT and Data Center demands. We are also providing a firmware upgrade release to all existing customers of the AC6000 allowing them to benefit with the latest advancements.”
The AC6000 is the first line-interactive UPS that both protects IT equipment from power outages and supplements the electrical grid during periods of peak energy consumption with its peak shave technology. Its industrial-grade lithium-ion battery pack supplies up to 6kW of power for six full minutes — 330 percent longer than legacy lead-acid batteries. It offers fast recharge to 90 percent in less than one hour, and delivers up to seven years of maintenance-free battery life. It’s up to 75 percent lighter than UPSs that use lead-acid batteries, and has a compact design that takes up just 2U of rack space in the data center.
The patent-pending peak shave technology in the AC6000 uses advanced energy management techniques to transfer to battery power during peak loads, thus reducing overall energy costs. The AC6000 is designed to maintain battery cell power balance, and it provides integrated safety electronics and thermal management for individual cells. It features a multifunctional LCD panel that displays critical performance metrics and alerts, and it supports serial and SNMP communications for remote monitoring and management.
“With low total cost of ownership, substantial energy savings and pricing that’s competitive with lead-acid products, the AC6000 delivers ROI in as little as two years,” Moore said. “Its lithium-ion battery pack delivers greater energy efficiency and more than seven year battery life while taking up less space within the data center cabinet. We believe this is the ideal solution for both modern web-scale data centers and edge computing applications where space is at a premium.”
The AC6000 is CE and UL listed and is available for purchase across the globe. To learn more about the AC6000 and purchase today, visit Enconnex AC6000 UPS .
About Enconnex
Enconnex designs and manufactures high-quality, cost-efficient solutions for data center infrastructure, including racks, cabinets and accessories, and connectivity, power, cooling and containment products. Enconnex also integrates cutting-edge solutions from a short list of technology partners who are recognized as industry leaders. Headquartered in Reno, Nev., Enconnex has offices and distribution facilities strategically located worldwide to serve the needs of its global customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom